JP2022533463A - エンザルタミドを含むナノ粒子 - Google Patents

エンザルタミドを含むナノ粒子 Download PDF

Info

Publication number
JP2022533463A
JP2022533463A JP2021569958A JP2021569958A JP2022533463A JP 2022533463 A JP2022533463 A JP 2022533463A JP 2021569958 A JP2021569958 A JP 2021569958A JP 2021569958 A JP2021569958 A JP 2021569958A JP 2022533463 A JP2022533463 A JP 2022533463A
Authority
JP
Japan
Prior art keywords
nanoparticles
weight
liquid
polyoxyethylene
enzalutamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569958A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020234448A5 (https=
JP2022533463A5 (https=
Inventor
ブルンナー・ハイコ
ギンドゥリス・フランク
Original Assignee
ヘルム・アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルム・アクチエンゲゼルシャフト filed Critical ヘルム・アクチエンゲゼルシャフト
Publication of JP2022533463A publication Critical patent/JP2022533463A/ja
Publication of JPWO2020234448A5 publication Critical patent/JPWO2020234448A5/ja
Publication of JP2022533463A5 publication Critical patent/JP2022533463A5/ja
Priority to JP2025071092A priority Critical patent/JP2025118693A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021569958A 2019-05-23 2020-05-22 エンザルタミドを含むナノ粒子 Pending JP2022533463A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025071092A JP2025118693A (ja) 2019-05-23 2025-04-23 エンザルタミドを含むナノ粒子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176304.4 2019-05-23
EP19176304 2019-05-23
EP19209182 2019-11-14
EP19209182.5 2019-11-14
PCT/EP2020/064268 WO2020234448A1 (en) 2019-05-23 2020-05-22 Nanoparticles comprising enzalutamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025071092A Division JP2025118693A (ja) 2019-05-23 2025-04-23 エンザルタミドを含むナノ粒子

Publications (3)

Publication Number Publication Date
JP2022533463A true JP2022533463A (ja) 2022-07-22
JPWO2020234448A5 JPWO2020234448A5 (https=) 2023-05-29
JP2022533463A5 JP2022533463A5 (https=) 2023-05-29

Family

ID=70861458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569958A Pending JP2022533463A (ja) 2019-05-23 2020-05-22 エンザルタミドを含むナノ粒子
JP2025071092A Pending JP2025118693A (ja) 2019-05-23 2025-04-23 エンザルタミドを含むナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025071092A Pending JP2025118693A (ja) 2019-05-23 2025-04-23 エンザルタミドを含むナノ粒子

Country Status (5)

Country Link
US (2) US20220249388A1 (https=)
EP (1) EP3972569A1 (https=)
JP (2) JP2022533463A (https=)
CA (1) CA3141534A1 (https=)
WO (1) WO2020234448A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915546A1 (de) * 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Verwendung von säure als lösungsmittel für präzipitationen
WO2024127361A1 (en) * 2022-12-16 2024-06-20 Ferring B.V. Enzalutamide nanocrystals, methods and compositions
EP4651860A1 (en) 2023-01-18 2025-11-26 HELM Pharmaceuticals GmbH Crystalline nanoparticles comprising enzalutamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
AU4910300A (en) 1999-04-08 2000-11-14 Bernd Penth Method and device for carrying out chemical and physical processes
CA2436418A1 (en) 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
CA2435721A1 (en) 2001-01-31 2002-08-08 Kraft Foods Holdings, Inc. Production of capsules and particles for improvement of food products
ES2257968B1 (es) 2005-01-28 2007-07-01 Universidad De Sevilla Procedimiento y dispositivo para la obtencion de particulas de tamaño micro y nanometrico.
DE102005017777A1 (de) 2005-04-13 2006-10-19 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Partikelsuspensionen
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DE102005053862A1 (de) 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
EP2550092B1 (de) 2010-03-22 2018-08-15 Instillo GmbH Verfahren zur herstellung von mikro- oder nanopartikeln
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
US9901893B2 (en) 2013-03-28 2018-02-27 Instillo Gmbh Apparatus and method for producing dispersions and solids
CA2940984A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
DE102016101232A1 (de) 2016-01-25 2017-07-27 Instillo Gmbh Verfahren zum Herstellen von Emulsionen
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens

Also Published As

Publication number Publication date
EP3972569A1 (en) 2022-03-30
CA3141534A1 (en) 2020-11-26
JP2025118693A (ja) 2025-08-13
WO2020234448A1 (en) 2020-11-26
US20250262166A1 (en) 2025-08-21
US20220249388A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US12576071B2 (en) Pharmaceutical compositions
US10668016B2 (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
JP6192244B2 (ja) 改良されたバイオアベイラビリティを有する薬学的組成物
US20250262166A1 (en) Nanoparticles comprising enzalutamide
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN109475553A (zh) 尼洛替尼的药物组合物
RS62422B1 (sr) Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina
JP7570696B2 (ja) ６－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）ニコチンアミドを含有する非晶質固体分散体
JP2010521494A (ja) 麻薬性および非麻薬性鎮痛剤の組み合わせ
JPWO2020234448A5 (https=)
JP2026504836A (ja) エンザルタミドを含む結晶性ナノ粒子
EP3989942A1 (en) Mesoporous polymeric particulate material
HK40045939A (en) Pharmaceutical composition with improved bioavailability
HK40047361A (en) Pharmaceutical composition with improved bioavailability
KR20150093510A (ko) 도세탁셀을 포함하는 경구용 고형지질나노입자 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241225